Nkarta

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Nkarta and other ETFs, options, and stocks.

About NKTX

Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm’s product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells.

CEO

Paul J. Hastings

CEOPaul J. Hastings

Employees

157

Employees157

Headquarters

South San Francisco, California

HeadquartersSouth San Francisco, California

Founded

2005

Founded2005

Employees

157

Employees157

NKTX Key Statistics

Market cap

123.82M

Market cap123.82M

Price-Earnings ratio

-1.15

Price-Earnings ratio-1.15

Dividend yield

—

Dividend yield—

Average volume

494.19K

Average volume494.19K

High today

$1.79

High today$1.79

Low today

$1.74

Low today$1.74

Open price

$1.74

Open price$1.74

Volume

274.37K

Volume274.37K

52 Week high

$8.23

52 Week high$8.23

52 Week low

$1.31

52 Week low$1.31

Analyst ratings

86%

of 7 ratings

Buy

85.7%

Hold

14.3%

Sell

People also own

Based on the portfolios of people who own NKTX. This list is generated using Robinhood data, and it’s not a recommendation.